Impact of combination evidence based medical treatment in patients with acute coronary syndromes in various TIMI risk groups.

T he term acute coronary syndrome (ACS) refers to a spectrum of acute severe cardiac disorders which include unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST segment elevation myocardial infarction (STEMI). Patients presenting with ACS represent a major health problem, accounting for 2.5 million hospitalisations and 500 000 deaths annually in the USA alone. We have previously demonstrated that use of combination evidence based medical treatments including antiplatelet agents, b blockers, statins, and angiotensin converting enzyme (ACE) inhibitors is independently and strongly associated with lower six month mortality in patients with ACS. In the present study we assessed the treatment effect of combination therapy in patients stratified according to their risk of future cardiovascular events according to the thrombolysis in myocardial infarction (TIMI) risk score.